CD19 and measles: CD19− BMPC display markers of advanced maturity and seem to contain a higher amount of long-lived PC than their CD19-expressing counterparts (4, 5), they persist after CD19-directed chimeric antigen receptor (CAR) T-cell therapy in B cell malignancies and produce IgG specific to tetanus toxoid, mumps and measles (12).